GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Genocea Biosciences Inc (OTCPK:GGNNQ) » Definitions » EV-to-EBIT

Genocea Biosciences (Genocea Biosciences) EV-to-EBIT : 0.00 (As of Jun. 05, 2024)


View and export this data going back to 2018. Start your Free Trial

What is Genocea Biosciences EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Genocea Biosciences's Enterprise Value is $0.00 Mil. Genocea Biosciences's EBIT for the trailing twelve months (TTM) ended in Mar. 2022 was $-36.12 Mil. Therefore, Genocea Biosciences's EV-to-EBIT for today is 0.00.

The historical rank and industry rank for Genocea Biosciences's EV-to-EBIT or its related term are showing as below:

GGNNQ' s EV-to-EBIT Range Over the Past 10 Years
Min: -13.79   Med: -1.6   Max: 0.86
Current: 0.13

During the past 11 years, the highest EV-to-EBIT of Genocea Biosciences was 0.86. The lowest was -13.79. And the median was -1.60.

GGNNQ's EV-to-EBIT is not ranked
in the Biotechnology industry.
Industry Median: 9.61 vs GGNNQ: 0.13

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Genocea Biosciences's Enterprise Value for the quarter that ended in Mar. 2022 was $0.00 Mil. Genocea Biosciences's EBIT for the trailing twelve months (TTM) ended in Mar. 2022 was $-36.12 Mil. Genocea Biosciences's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2022 was %.


Genocea Biosciences EV-to-EBIT Historical Data

The historical data trend for Genocea Biosciences's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Genocea Biosciences EV-to-EBIT Chart

Genocea Biosciences Annual Data
Trend Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21
EV-to-EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.64 -0.52 -0.98 -1.71 -1.48

Genocea Biosciences Quarterly Data
Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22
EV-to-EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.44 -2.67 -2.37 -1.48 -1.90

Competitive Comparison of Genocea Biosciences's EV-to-EBIT

For the Biotechnology subindustry, Genocea Biosciences's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Genocea Biosciences's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Genocea Biosciences's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Genocea Biosciences's EV-to-EBIT falls into.



Genocea Biosciences EV-to-EBIT Calculation

Genocea Biosciences's EV-to-EBIT for today is calculated as:

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=0.000/-36.118
=0.00

Genocea Biosciences's current Enterprise Value is $0.00 Mil.
Genocea Biosciences's EBIT for the trailing twelve months (TTM) ended in Mar. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $-36.12 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Genocea Biosciences  (OTCPK:GGNNQ) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Genocea Biosciences's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2022 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Mar. 2022 ) =EBIT / Enterprise Value (Q: Mar. 2022 )
=-36.118/0
= %

Genocea Biosciences's Enterprise Value for the quarter that ended in Mar. 2022 was $0.00 Mil.
Genocea Biosciences's EBIT for the trailing twelve months (TTM) ended in Mar. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $-36.12 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Genocea Biosciences EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Genocea Biosciences's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Genocea Biosciences (Genocea Biosciences) Business Description

Traded in Other Exchanges
N/A
Address
100 Acorn Park Drive, Cambridge, MA, USA, 02140
Genocea Biosciences Inc is a US-based biopharmaceutical company which is engaged in developing novel vaccines and immunotherapies to address diseases with significant unmet needs. Its product candidate includes GEN-003 which is an immunotherapy for the treatment of genital herpes as well as it owns a pre-clinical immuno-oncology program focused on personalized cancer vaccines. The company focuses on developing vaccines and immunotherapies for unmet needs through its AnTigen Lead Acquisition System, which is used to design vaccines and immunotherapies. Genocea operates its business through the single segment being Developing and Commercializing vaccines.
Executives
John Lunger director C/O ADAPTIMMUNE THERAPEUTICS PLC, 60 JUBILEE AVE, MILTON PARK, ABINGDON, OXFORDSHIRE X0 OX14 4RX
Jennifer Lyn Herron director C/O GENOCEA BIOSCIENCES, INC., 100 ACORN PARK DRIVE 5TH FLOOR, CAMBRIDGE MA 02140
Jacquelyn L Sumer officer: CHIEF LEGAL & COMPLIANCE OFF C/O GENOCEA BIOSCIENCES, INC., 100 ACORN PARK DRIVE 5TH FLOOR, CAMBRIDGE MA 02140
Stapleton Raymond D Jr officer: EVP PHARM SCI & MFG C/O GENOCEA BIOSCIENCES, INC., 100 ACORN PARK DRIVE 5TH FLOOR, CAMBRIDGE MA 02140
Paul Edward Walker 10 percent owner 1954 GREENSPRING DRIVE, SUITE 600, TIMONIUM MD 21093
Gisela Schwab director 6701 KAISER DRIVE, FREMONT CA 94555
Diantha Duvall officer: CHIEF FINANCIAL OFFICER C/O GENOCEA BIOSCIENCES, INC., 100 ACORN PARK DRIVE 5TH FLOOR, CAMBRIDGE MA 02140
Girish N Aakalu officer: CHIEF BUSINESS OFFICER C/O GENOCEA BIOSCIENCES, INC., 100 ACORN PARK DRIVE, 5TH FLOOR, CAMBRIDGE MA 02140
Narinderjeet Singh officer: SENIOR VP, PS&M C/O GENOCEA BIOSCIENCES, INC., 100 ACORN PARK DRIVE, 5TH FLOOR, CAMBRIDGE MA 02140
Pamela Carroll officer: SVP IMMUNO-ONCOLOGY C/O GENOCEA BIOSCIENCES, INC., 100 ACORN PARK DRIVE, 5TH FLOOR, CAMBRIDGE MA 02140
Thomas Andrew Davis officer: CHIEF MEDICAL OFFICER 65 WEST WATKINS MILL ROAD, GAITHERSBURG MD 20878
Derek M Meisner officer: SENIOR VP AND GENERAL COUNSEL C/O GENOCEA BIOSCIENCES, INC., 100 ACORN PARK DRIVE, 5TH FLOOR, CAMBRIDGE MA 02140
Michael Alfieri officer: Principle Financial Officer C/O GENOCEA BIOSCIENCES, INC., 100 ACORN PARK DRIVE, 5TH FLOOR, CAMBRIDGE MA 02140
Howard Mayer director C/O GENOCEA BIOSCIENCES, INC., 100 ACORN PARK DRIVE, 5TH FLOOR, CAMBRIDGE MA 02140
Cooper Ronald Harold Wilfred director C/O GENOCEA BIOSCIENCES, INC., 100 ACORN PARK DRIVE, 5TH FLOOR, CAMBRIDGE MA 02140

Genocea Biosciences (Genocea Biosciences) Headlines

From GuruFocus

Genocea Provides Fourth Quarter 2021 Corporate Update

By GuruFocusNews GuruFocusNews 03-10-2022

Genocea Announces Wind Down of Operations and Delisting From NASDAQ

By GuruFocusNews GuruFocusNews 05-24-2022

Genocea to Present at Upcoming Conferences

By Marketwired Marketwired 09-28-2021

Genocea Announces Wind Down of Operations and Delisting From NASDAQ

By GuruFocusNews GuruFocusNews 06-13-2022

Genocea to Present at the 32nd Annual Oppenheimer Healthcare Conference

By GlobeNewswire GlobeNewswire 03-14-2022

Genocea Biosciences Provides Corporate Update

By GuruFocusNews GuruFocusNews 01-04-2022

Genocea to Present Clinical and Preclinical Data at AACR Annual Meeting

By GlobeNewswire GlobeNewswire 03-08-2022

Genocea Provides Third Quarter 2021 Corporate Update

By Marketwired Marketwired 10-28-2021